Have to chuckle every time someone brings up listing in the US
On a serious note, Aussie biotechs listed on the ASX (dual listed or not) have been very innovative and performing quite well in 2024 both fundamentally and SP-wise. Some are expecting M&A activity in the next 1-2 years including RAC (may be in 2 years?) that will bring even more focus to ASX biotechs.
Have to chuckle every time someone brings up listing in the US...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
0.120(6.80%) |
Mkt cap ! $321.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.93 | $1.78 | $563.4K | 302.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 108 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 4926 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |